Provided by Tiger Trade Technology Pte. Ltd.

GlaxoSmithKline PLC

47.18
-0.9900-2.06%
Post-market: 47.500.3200+0.68%19:58 EDT
Volume:7.90M
Turnover:376.02M
Market Cap:95.43B
PE:15.09
High:48.23
Open:48.16
Low:47.13
Close:48.17
52wk High:61.70
52wk Low:42.85
Shares:2.02B
Float Shares:1.94B
Volume Ratio:2.14
T/O Rate:0.41%
Dividend:1.80
Dividend Rate:3.81%
EPS(TTM):3.13
EPS(LYR):3.74
ROE:33.38%
ROA:10.01%
PB:4.09
PE(LYR):12.63

Loading ...

Citi Initiates a Hold Rating on GlaxoSmithKline (GSK)

TIPRANKS
·
Jul 25

J.P. Morgan Sticks to Its Sell Rating for GlaxoSmithKline (GSK)

TIPRANKS
·
Jul 24

GSK Canada Wins Approval for Prefilled Shingrix Syringe

MT Newswires Live
·
Jul 24

GSK Plc Expected to Post Earnings of $1.24 a Share - Earnings Preview

Reuters
·
Jul 24

Sector Update: Healthcare Stocks Softer Late Afternoon

MT Newswires Live
·
Jul 23

GSK Gets U.S. Approval for Jideytro for Certain Lung Cancers

Dow Jones
·
Jul 23

Earning Preview: GlaxoSmithKline PLC Q2 revenue is expected to increase by 3.77%, and institutional views are bullish

Earnings Agent
·
Jul 22

GSK’s New Malaria Candidate Advances With Key Drug-Interaction Study

TIPRANKS
·
Jul 22

GSK’s ViiV Healthcare to present new data on INSTI-focused portfolio

TIPRANKS
·
Jul 21

GSK plc Stock (GSK) Closed Down by 3.17% on Jul 20: Facts Behind the Movement

TradingKey
·
Jul 21

Movement Alert|GSK Falls 3.02% in Regular Trading, Termination of Camlipixant Chronic Cough Program Marks $2 Billion Acquisition Pipeline Failure

Market Focus
·
Jul 21

GSK Updates Key Pediatric Flu Study, Signaling Quiet Upside for Its Antiviral Portfolio

TIPRANKS
·
Jul 21

GSK Falls Monday, Underperforms Market

Dow Jones
·
Jul 21

GSK announces EMA accepted submission to update Bexsero label

TIPRANKS
·
Jul 20

GSK Cough Drug Failure Disappoints, but Market was Cautious

Dow Jones
·
Jul 20

Dow Jones Top Company Headlines at 7 PM ET: Walmart Further Shuffles Top Executives | SpaceX ...

Dow Jones
·
Jul 18

GSK plc Stock (GSK) Moved Down by 3.06% on Jul 17: Drivers Behind the Movement

TradingKey
·
Jul 18

Movement Alert|GSK Falls 3.02% in Regular Trading, Discontinues Camlipixant Development After Phase 3 Failure in Refractory Chronic Cough

Market Focus
·
Jul 18

GSK’s ALANIS Trial: Fresh Momentum in AL Amyloidosis Could Reshape Investor Views

TIPRANKS
·
Jul 18

GSK Explores Heart Health Upside From Its Next-Gen Vaccines

TIPRANKS
·
Jul 18